

1 **Shared N417-dependent epitope on the SARS-CoV-2 Omicron, Beta and Delta-**
2 **plus variants**

3

4 Thandeka Moyo-Gwete^{1,2}, Mashudu Madzivhandila^{1,2}, Nonhlanhla N Mkhize^{1,2},
5 Prudence Kgagudi^{1,2}, Frances Ayres^{1,2}, Bronwen E Lambson^{1,2}, Nelia P
6 Manamela^{1,2}, Simone I Richardson^{1,2}, Zanele Makhado^{1,2}, Mieke A van der Mescht³,
7 Zelda de Beer⁴, Talita Roma de Villiers⁴, Wendy A Burgers^{5,6}, Ntobeko A B Ntusi^{6,7,8},
8 Theresa Rossouw³, Veronica Ueckermann⁹, Michael T Boswell⁹,
9 Penny L Moore^{1,2,5,10*}

10 ¹National Institute for Communicable Diseases of the National Health Laboratory
11 Service, Johannesburg, South Africa. ²MRC Antibody Immunity Research Unit,
12 School of Pathology, Faculty of Health Sciences, University of the Witwatersrand,
13 Johannesburg, South Africa. ³Department of Immunology, Faculty of Health
14 Sciences, University of Pretoria, Pretoria, South Africa. ⁴Tshwane District Hospital,
15 Pretoria, South Africa. ⁵Institute of Infectious Disease and Molecular Medicine,
16 Division of Medical Virology, Department of Pathology, University of Cape Town,
17 Cape Town, South Africa. ⁶Wellcome Centre for Infectious Diseases Research in
18 Africa, University of Cape Town, Cape Town, South Africa. ⁷Division of Cardiology,
19 Department of Medicine, University of Cape Town and Groote Schuur Hospital,
20 Cape Town, South Africa. ⁸Cape Heart Institute, Faculty of Health Sciences,
21 University of Cape Town, Cape Town, South Africa. ⁹Division for Infectious
22 Diseases, Department of Internal Medicine, Steve Biko Academic Hospital and
23 University of Pretoria, Pretoria, South Africa. ¹⁰Centre for the AIDS Programme of
24 Research in South Africa (CAPRISA), Durban, South Africa.

25 *Corresponding author

26

27

28

29 **Abstract**

30

31 As SARS-CoV-2 continues to evolve, several variants of concern (VOCs) have
32 arisen which are defined by multiple mutations in their spike proteins. These VOCs
33 have shown variable escape from antibody responses, and have been shown to
34 trigger qualitatively different antibody responses during infection. By studying plasma
35 from individuals infected with either the original D614G, Beta or Delta variants, we
36 show that the Beta and Delta variants elicit antibody responses that are overall more
37 cross-reactive than those triggered by D614G. Patterns of cross-reactivity varied,
38 and the Beta and Delta variants did not elicit cross-reactive responses to each other.
39 However, Beta-elicited plasma was highly cross-reactive against Delta plus (Delta+)
40 which differs from Delta by a single K417N mutation in the receptor binding domain,
41 suggesting the plasma response targets the N417 residue. To probe this further, we
42 isolated monoclonal antibodies from a Beta-infected individual with plasma
43 responses against Beta, Delta+ and Omicron, which all possess the N417 residue.
44 We isolated a N417-dependent antibody, 084-7D, which showed similar
45 neutralization breadth to the plasma. The 084-7D mAb utilized the IGHV3-23*01
46 germline gene and had similar somatic hypermutations compared to previously
47 described public antibodies which target the 417 residue. Thus, we have identified a
48 novel antibody which targets a shared epitope found on three distinct VOCs,
49 enabling their cross-neutralization. Understanding antibodies targetting escape
50 mutations such as K417N, which repeatedly emerge through convergent evolution in
51 SARS-CoV-2 variants, may aid in the development of next-generation antibody
52 therapeutics and vaccines.

53

54

55

56

57 **Importance**

58

59 The evolution of SARS-CoV-2 has resulted in variants of concern (VOCs) with
60 distinct spike mutations conferring varying immune escape profiles. These variable
61 mutations also influence the cross-reactivity of the antibody response mounted by
62 individuals infected with each of these variants. This study sought to understand the
63 antibody responses elicited by different SARS-CoV-2 variants, and to define shared
64 epitopes. We show that Beta and Delta infection resulted in antibody responses that
65 were more cross-reactive compared to the original D614G variant, but each with
66 differing patterns of cross-reactivity. We further isolated an antibody from Beta
67 infection, which targeted the N417 site, enabling cross-neutralization of Beta, Delta+
68 and Omicron, all of which possess this residue. The discovery of antibodies which
69 target escape mutations common to multiple variants highlights conserved epitopes
70 to target in future vaccines and therapeutics.

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88 **Introduction**

89

90 Since the emergence of SARS-CoV-2 in 2019, several variants of concern (VOCs)
91 and interest (VOIs) have emerged. Many of these variants contain mutations in the
92 spike protein that confer escape from neutralizing antibodies (1). The first
93 neutralization-resistant VOC identified, Beta, contained receptor binding domain
94 (RBD) mutations at positions K417N and E484K, which confer escape from Class I
95 and Class II neutralization antibodies, respectively (2, 3). These mutations have
96 since been observed in multiple variants. One such example is the charge-altering
97 E484K/Q/A mutation, which occurs in several variants including Gamma, the Delta
98 lineage, C.1.2 and A.VOI.V2 (1, 4-6). The E484K mutation is also present in Omicron
99 (first identified in South Africa) which is the most neutralization-resistant variant
100 identified to date, evading both convalescent and vaccine-elicited antibody
101 responses (5, 7-9).

102

103 Similarly, the K417N mutation found in the Beta variant has also emerged in other
104 VOC/VOIs throughout the world. This mutation results in a change from a positively
105 charged residue (lysine, K) to an uncharged asparagine (N) residue - a difference
106 large enough to prevent binding of antibodies dependent on this epitope (3). This
107 substitution results in escape from Class I neutralizing antibodies such as the
108 therapeutic monoclonal antibody (mAb), etesevimab (10, 11). The K417N mutation
109 also occurs in a sublineage of Delta, called Delta plus (Delta+), and in the Omicron
110 variant (BA.1) and its sub-lineages (BA.2, BA.3, BA.4 and BA5) (12), indicating that
111 an antibody that targets this site may cross-neutralize these variants.

112

113 The high levels of convergent evolution observed globally between variants indicates
114 that at a population level, neutralizing antibodies target similar regions of the SARS-
115 CoV-2 spike protein. This is supported by numerous monoclonal antibody (mAb)
116 isolation studies which identified the RBD as the major target of the neutralizing
117 antibody response, regardless of the infecting variant or type of vaccination (13-17).
118 However, there is substantial evidence that the antibody response towards the RBD
119 differs in fine specificity depending on which variant triggered the infection. The
120 original (D614G) variant triggers antibodies with very low levels of cross-reactivity to
121 the Beta variant (3). Responses elicited by the Beta variant however, exhibit higher

122 levels of cross-reactivity towards the D614G and the Gamma variant (18) but not
123 against the Delta variant (19, 20). Similarly, Delta-elicited responses have low cross-
124 reactivity towards the Beta variant (15, 21). It has therefore been suggested that the
125 Beta and Delta variants took divergent evolutionary pathways towards distinct
126 groupings or “serotypes”, with the D614G original variant being serologically closer
127 to Delta than Beta (19). The Omicron variant elicits predominantly Omicron-specific
128 antibodies, with poor cross-reactivity against Delta and C.1.2 and D614G, and a
129 dramatic 31-fold reduction in activity against Beta (22). Defining the fine specificity of
130 neutralizing antibodies elicited by the different variants is therefore important to
131 determine whether there are common responses targeting divergent variants.

132

133 In this study, we compared the cross-reactivity of plasma responses during three
134 separate SARS-CoV-2 waves in South Africa. Each epidemic wave in South Africa
135 was dominated by a distinct variant; first D614G, then Beta, followed by Delta. We
136 first assessed the neutralizing antibody responses elicited by each of the three
137 variants against a panel of circulating VOCs and SARS-CoV-1. We show that Beta
138 and Delta infection elicited more cross-reactive responses than the D614G variant,
139 though the patterns of cross-reactivity were different. Furthermore, Beta-elicited
140 plasma potentially neutralized the Delta+ variant compared to the Delta variant,
141 suggesting these cross-reactive antibodies may target the N417 residue, as this is
142 the only spike mutation that differentiates these two variants. To confirm this, we
143 isolated and characterized a mAb from a Beta-infected individual who showed
144 plasma neutralization of Beta, Delta+ and Omicron. Epitope mapping revealed that
145 this mAb, 084-7D, recapitulated much of the plasma breadth and was heavily
146 dependent on a shared N417 epitope. The discovery of cross-reactive mAbs may aid
147 in the development of universal SARS-CoV-2 therapeutic antibodies and inform the
148 design of booster vaccines.

149

150

151

152

153

154 **Results**

155

156 **Neutralizing responses triggered by variants of concern possess differential**
157 **patterns of cross-reactivity**

158

159 We first compared antibody responses in unvaccinated individuals infected by VOCs
160 circulating in three distinct SARS-CoV-2 epidemiological waves in South Africa from
161 May 2020 to July 2021. In each wave, sampling occurred at the time when each
162 respective variant was responsible for at least 90% of infections, and sequencing in
163 a subset of matched nasal swabs confirmed the infecting variant. We investigated
164 how well plasma elicited by D614G, Beta and Delta variants neutralized multiple
165 VOCs, as well as SARS-CoV-1 (**Figure 1A and 1B**). D614G-elicited plasma
166 triggered robust neutralization of the matched D614G spike (autologous
167 neutralization), but showed very low levels of cross-reactivity, with a 12-15-fold
168 decrease in neutralization towards all SARS-CoV-2 VOCs tested and to SARS-CoV-
169 1 (**Figure 1A**). In contrast, as we previously reported, plasma from Beta infections
170 was highly cross-reactive against the D614G variant (2.9 fold reduction) (18) but
171 showed less cross-reactivity against other VOCs, with reductions against Delta,
172 Omicron and SARS-CoV-1 of 11.3-fold, 9.4-fold and 9.3-fold, respectively (**Figure**
173 **1A**). We also tested plasma from Delta-infected individuals and found that although
174 autologous titers against the matched spike were very high, there was a 15-41-fold
175 drop in neutralization potency across VOC/VOIs and SARS-CoV-1. The higher level
176 of cross-reactivity for the D614G variant (15-fold drop in potency, compared to Beta
177 (35-fold drop) in Delta-elicited plasma is consistent with what others have reported
178 (19, 21).

179

180 To get a measure of the degree and patterns of cross-reactivity for each variant, we
181 compared the geometric mean titers (GMTs) of the plasma response elicited by the
182 three variants towards various VOCs and SARS-CoV-1 using a spider plot (**Figure**
183 **1B**). Each variant triggered the highest responses against their corresponding
184 autologous virus as expected. Furthermore, the extent of autologous neutralization
185 varied, with Delta triggering particularly high autologous responses (GMT: 2,819),
186 compared to Beta (GMT:1,282) or D614G (GMT:621), likely a consequence of the
187 high viral loads in Delta infections (23). We therefore calculated a single measure of

188 breadth, by assessing the cumulative area under the curve (AUC) value for all
189 variants, normalized relative to the GMT of the autologous virus to account for
190 differential potency of responses (**Figure 1B**). Beta- and Delta-elicited responses
191 were both approximately 2-fold higher (AUC: 114 and 103) than D614G (AUC: 52)
192 (**Figure 1B**), indicating that the neutralizing responses triggered by these two
193 variants were more cross-reactive than those elicited by the early circulating SARS-
194 CoV-2 variant.

195

196 Although other sites, such as the RBD Class III antibody binding site, have
197 previously been implicated as targets of the Beta-elicited responses (14) the N417K
198 mutation in the Beta RBD has also been shown to be a dominant target of Beta-
199 elicited plasma (24, 25). To assess whether antibodies to this site accounted for the
200 breadth in Beta-infected individuals, we tested Beta plasma against the Delta+
201 variant, which differs from Delta only at K417N, the same mutation that is also found
202 in Beta (**Figure 1C**). This mutation is the only shared mutation in the RBD regions of
203 the Beta and Delta+ lineages. Compared to the Beta response towards Delta which
204 showed a significant drop in potency (6.1-fold), there was only a 2.5-fold drop in
205 potency against Delta+ (**Figure 1C**). These data confirm the importance of the N417
206 residue as a target of Beta-elicited cross-reactive neutralizing antibody responses.

207

208 **Isolation and characterization of a SARS-CoV-2 cross-reactive, neutralizing** 209 **monoclonal antibody from a Beta-infected individual**

210

211 To assess whether the N417 residue was a target of Beta-elicited mAb responses,
212 we sought to isolate mAbs from a Beta-infected individual who developed potent
213 responses towards the Beta variant and was cross-reactive towards other VOCs. We
214 previously recruited participant SA-01-0084 (084) into our cohort of hospitalized
215 patients infected with the Beta variant (18). This participant was female, below the
216 age of 60, HIV-uninfected, and had their blood drawn two days after a positive
217 SARS-CoV-2 RT-PCR test (**Figure 2A**). Plasma from donor 084 potently neutralized
218 Beta ($ID_{50} = 7,613$) and Delta+ ($ID_{50} = 12,083$) pseudoviruses (**Figure 2B**). The 084
219 plasma also potently neutralized Omicron ($ID_{50} = 9,882$). However, it did not
220 neutralize the D614G, Delta or SARS-CoV-1 pseudovirus and had weak
221 neutralization against Gamma and A.VOI.V2 ($ID_{50} < 120$) (**Figure 2B**). The high cross-

222 reactivity of the plasma towards Delta+ was similar to what we observed with other
223 Beta-elicited plasma (**Figure 1C**).

224 We performed single cell sorting of the participant's peripheral blood mononuclear
225 cells (PBMCs). Using Beta and D614G spike proteins as cell sorting baits, we sorted
226 a total of 68 cells, with approximately 58 of the cells being Beta-specific and the rest
227 of the cells being double-positive (**Figure 2C**). We identified an IgG1 mAb, 084-7D,
228 which bound to the Beta spike antigen (**Figure 2**). We tested the functionality of mAb
229 084-7D by first examining its neutralizing activity against the same VOCs we had
230 tested the plasma against (**Figure 2D**). The 084-7D mAb showed a very similar
231 cross-reactivity pattern to the matched sera, exhibiting potent neutralization of Beta
232 ($IC_{50} = 0.10 \mu\text{g/ml}$) and Delta+ ($IC_{50} = 0.01 \mu\text{g/ml}$), though slightly lower activity
233 against Omicron ($IC_{50} = 3.31 \mu\text{g/ml}$) than was observed in the plasma. The mAb did
234 not neutralize SARS-CoV-1 or the other VOC/VOIs tested (**Figure 2D**). These data
235 indicate that this mAb recapitulated the dominant response in the plasma, though it
236 did not entirely account for Omicron plasma neutralization.

237

238 **084-7D mAb epitope mapping reveals spike target that is highly dependent on**
239 **the N417 residue**

240

241 To map the spike target of the mAb, we conducted binding experiments using a
242 SARS-CoV-2-specific enzyme linked immunosorbent assay (ELISA). The antibody
243 bound the full Beta spike but not the D614G spike as expected based on the
244 neutralization assay results (**Figure 2E**). No binding was observed for either the Beta
245 or D614G N-terminal domain (NTD) proteins, but strong binding was detected
246 towards the Beta RBD (**Fig. 2E**). We expressed single mutants representing the
247 three RBD mutations found in the Beta variant - K417N, E484K and N501Y - in an
248 SBD (subdomain 1) backbone and tested whether the antibody was able to
249 recognize any of the Beta mutations. The 084-7D mAb bound to the K417N mutant
250 but did not bind to the D614G SBD or E484K and N501Y single mutants (**Figure**
251 **2E**). Overall, these data suggest that the 084-7D mAb is dependent on the N417
252 residue present in the Beta RBD.

253

254 **mAb 084-7D exhibits Fc effector functionality, particularly against the Beta**
255 **variant**

256

257 We have previously shown that, in addition to neutralization, the Beta variant triggers
258 cross-reactive Fc functionality compared to D614G (26). We therefore analyzed the
259 ability of the 084-7D mAb to mediate antibody-dependent cellular phagocytosis
260 (ADCP) and measured the ability of mAb 084-7D to cross-link CD16 and SARS-
261 CoV-2 spike proteins expressed on cells as a proxy for antibody-dependent cellular
262 cytotoxicity (ADCC). Both of these effector functions have been shown to contribute
263 to decreased severity of SARS-CoV-2 infection and are required for optimal
264 protection from infection by monoclonal antibodies (27). We compared mAb 084-7D
265 to control mAbs, P2B-2F6 and CR3022. The 084-7D mAb mediated strong
266 phagocytic activity against the Beta variant (AUC: 1,513) but up to 3-fold weaker
267 activity against the D614G and Omicron variants (AUC: 209 and 468 respectively)
268 (**Figure 3A**). In comparison, P2B-2F6, which targets a Class II RBD epitope,
269 mediated strong ADCP against D614G, but much lower levels against Beta and no
270 activity against Omicron, as expected. The CR3022 mAb showed cross-reactive
271 ADCP to all three variants, as previously reported (22). The 084-7D mAb exhibited
272 ADCC activity against the Beta (AUC: 25,937) and Omicron (AUC: 15,551) variants
273 while no activity was detected for the D614G variant (**Figure 3B**). The P2B-2F6 mAb
274 displayed strong ADCC activity against the D614G variant (AUC:113,631) as
275 expected but no activity towards Beta and Omicron. CR3022 had similar activity
276 across the three variants. Overall, the 084-7D mAb mediated Fc effector functionality
277 with similar patterns of cross-reactivity to that observed in neutralization, exhibiting
278 ADCP and ADCC activity against the Beta variant but reduced activity against
279 Omicron.

280

281 **084-7D is related to a broad and potent N417-dependent antibody isolated from** 282 **early pandemic infection**

283

284 We next investigated the genetics of mAb 084-7D to determine whether it could be
285 classified amongst other RBD-targeting mAbs based on germline gene usage and
286 epitope targeting (**Figure 4**). The 084-7D antibody was isolated as an IgG1, IgA1
287 and IgM but was cloned and tested as an IgG1 for this study (**Figure 1A**). The mAb
288 uses the 3-23*01 variable heavy (VH) chain gene, exhibiting 5.9% somatic
289 hypermutation in the variable gene region, despite being isolated early in infection

290 **(Figure 4A)**. The 1-5*03 variable kappa (VK) chain gene is used by this mAb, and
291 we observed less somatic hypermutation in the VK gene (2.9%) compared to the
292 heavy chain. We compared the 084-7D mAb to a previously reported SARS-CoV-2
293 RBD-specific antibody, CAB-A17, that utilizes the VH3-53*01 germline gene, which
294 is similar to VH3-23*01 with 91% identity. The CAB-A17 lineage developed VOC
295 cross-neutralization through interactions with the N417 residue, suggesting similar
296 epitope targeting compared to mAb 084-7D (28).

297

298 Sheward *et al.* identified four key mutations in the heavy chain of the broad mAb,
299 CAB-A17, which likely contributed to the increased breadth observed: G26E, T28I,
300 S53P and Y58F (Kabat numbering). Alignment of the VH3-23*01 (used by 084-7D),
301 VH3-53*01 (used by CAB-A17), CAB-A17 and 084-7D heavy chain sequences
302 (truncated at the CDRH3 region) showed that the 084-7D mAb had mutations at two
303 of the same key residues, T28S and S53G, although the amino acid changes
304 differed from the CAB-A17 mAb mutations (**Figure 4A**).

305

306 Furthermore, the light chain of Class I K417-targeting antibodies has been shown to
307 play a role in epitope interactions through the CDRL1 ²⁸VSSS³¹-motif (Kabat
308 numbering) (13, 28). We noted that the 084-7D mAb possessed a germline encoded
309 ISS-motif, which is similar to the CAB-A17 mAb which also had a deletion in this
310 region, resulting in an LST-motif (**Figure 4B**). Altogether, these data show that the
311 084-7D mAb is similar to a highly broad and potent mAb which targets a similar
312 epitope.

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332 **Discussion**

333

334 In this study, we investigated the cross-reactive potential of plasma elicited by three
335 different variants that circulated in South Africa during three sequential waves of
336 infection - the D614G, Beta and Delta variants. Antibodies generated by the Beta
337 and Delta variants exhibited higher levels of cross-reactivity as compared to those
338 triggered by the original D614G variant confirming that SARS-CoV-2 variants elicit
339 varying antibody responses, potentially targeting different epitopes on the spike
340 protein. Secondly, we used a mAb isolated from a Beta-infected donor to define a
341 N417-dependent neutralizing antibody epitope shared between the Beta, Delta+ and
342 Omicron variants. This mAb exhibited similar genetic features to a potent and broad
343 N417-dependent antibody, suggesting that this site may be commonly targeted by
344 SARS-CoV-2 cross-reactive mAbs.

345

346 The K417N mutation has been implicated in immune escape from Delta-elicited
347 plasma and this may explain the lack of cross-reactivity between Beta and Delta
348 antibody responses (15). In line with this, we found that although Delta+ and Delta
349 spike sequences only differ by one amino acid (N417 in Delta+ and K417 in Delta),
350 antibodies elicited by the Beta variant showed cross-reactivity against the Delta+ VOI
351 but very little cross-reactivity towards the Delta VOC. Our findings suggest that the
352 Beta-elicited plasma responses we tested were preferentially targeting an epitope
353 that was dependent on the N417 residue that is found in the Beta, Delta+ and
354 Omicron VOCs. Our data confirms findings by other groups who have shown that the
355 N417-directed response accounts for a large proportion of the Beta-elicited response
356 in some individuals (24, 25).

357

358 Here, we isolated an N417-dependent mAb from a Beta-infected individual which
359 neutralized and performed Fc effector function against the Beta, Delta+ and Omicron
360 VOCs. The 084-7D mAb utilizes the VH3-23*01 germline gene, and members of this

361 class of mAbs have previously been shown to target the RBD (29, 30). VH3 gene
362 families are well-documented in targeting this site, including Class I antibodies which
363 bind to the K417-residue (13, 29). The VH3 group of antibodies have been classed
364 as public antibodies suggesting that they can be easily elicited in SARS-CoV-2
365 infection and vaccination (29, 31, 32). Similar to the 084-7D mAb, low levels of
366 somatic hypermutation are needed for most VH3 SARS-CoV-2 antibodies to
367 neutralize their target, suggesting that germline-encoded sequences, such as in the
368 CDRH2 and CDRL2, play a sufficient role in epitope recognition (13). These
369 characteristics of mAb 084-7D make it attractive to pursue as a vaccine target.

370

371 Although many aspects of neutralization are germline encoded, increased somatic
372 hypermutation enhances the maturation of breadth to SARS-CoV-2 VOCs (33), as
373 for other pathogens (34, 35). As mAb 084-7D was isolated from blood drawn only
374 two days after testing positive for SARS-CoV-2, this antibody was isolated too early
375 to have accumulated substantial somatic hypermutation. Plasma from donor 084
376 collected at the same timepoint was highly potent against Omicron, but the 084-7D
377 mAb displayed less potency against this variant. This suggests that there may be
378 other antibodies in the plasma which are cross-reactive against Omicron.

379

380 The lack of neutralization and Fc effector of mAb 084-7D against Omicron compared
381 to the Beta and Delta+ variants may be impacted by the fact that the Beta and
382 Delta+ variants each possess three mutations in their RBD regions, including the
383 K417N mutations, whilst Omicron possesses at least 17 mutations in that region (5).
384 The numerous mutations clustered around the Y501 residue in Omicron may have
385 an impact on mAb 084-7D interactions as this region has been shown to be
386 important for Class I antibody CDRL1 interactions (29). Although our data focused
387 on the interaction between this mAb and the N417 residue, the complete epitope-
388 paratope interaction must be investigated through the determination of a high-
389 resolution structure. This will delineate the role of other residues in creating the full
390 epitope of this mAb to decipher its relatively lower levels of potency towards
391 Omicron.

392

393 A recently described mAb, CAB-A17, shares similar genetic and epitope-dependent
394 traits to mAb 084-7D (28). However, mAb CAB-A17 has substantially more breadth

395 across VOCs and is also more potent against Omicron than the 084-7D mAb (28).
396 Exploring the differences between the two mAbs may suggest a mechanism required
397 to achieve high levels of breadth and potency in this class of antibody. The CAB-A17
398 mAb contains key mutations that resulted in increased breadth towards the Omicron
399 variant - G26E, T28I, S53P and Y58F. The 084-7D mAb contains 2/4 of these
400 mutations although the residue changes differ - T28S and S53G. The changes in
401 mAb CAB-A17 at these sites are much more substantial, especially the serine to
402 proline change at position 53 that may alter the conformation of that region and
403 therefore affect epitope binding. These differences may contribute to the disparity in
404 breadth and potency between these two mAbs.

405

406 In addition to their distinct epitope-paratope interactions, the angle of approach is
407 likely different between the two mAbs. CAB-A17 makes interactions with the N417
408 residue through the Y33 residue on the heavy chain (28). mAb 084-7D possesses an
409 alanine at that position (A33) that would likely be unable to make strong contacts
410 with the asparagine at 417 due to its shorter side chain. Therefore, it is plausible that
411 mAb 084-7D interacts with the N417 residue using an alternative contact site(s) or
412 binds through a different angle of approach. It is important to note that the evolution
413 of the CAB-A17 mAb took place over seven months while 084-7D was isolated from
414 acute infection. Tracking the evolution of mAb 084-7D will reveal whether somatic
415 hypermutation led to increased potency and breadth and whether this maturation
416 mimicked the pathway used by CAB-A17 or followed an independent route.

417

418 The identification of another novel N417-dependent mAb that can neutralize various
419 VOC/VOIs indicates that this may be a good target for a cross-reactive response.
420 The CAB-A17 mAb was isolated earlier in the pandemic, presumably as a result of
421 D614G infection, while the 084-7D mAb was isolated from Beta infection, again
422 highlighting the universal targeting of this epitope by different variants. Despite the
423 divergence of variants into “serotypes” or “clusters”, we show that the antibody
424 response towards different variants can converge on shared epitopes. Finding mAbs
425 that target conserved sites across variants will likely aid in the development of
426 therapeutic mAb cocktails that can treat SARS-CoV-2 infection regardless of the
427 infecting variant.

428

430 **Materials and Methods**

431

432 *Cohort description*

433 Plasma samples from the first SARS-CoV-2 wave (D614G-infected) were obtained
434 from a previously described cohort across various sites in South Africa prior to
435 September 2020 (3). Second wave samples (Beta-infected) were obtained from a
436 cohort of patients admitted to Groote Schuur Hospital, Cape Town in December
437 2020 - January 2021 (18). Third wave samples (Delta-infected) were obtained from
438 the Steve Biko Academic Hospital, Tshwane from patients admitted in July 2021. In
439 all waves, samples were collected when more than 90% of SARS-CoV-2 cases in
440 South Africa were caused by the respective variants. Sequence confirmation was
441 only available for a subset of samples but all the samples that were sequenced
442 corresponded to the appropriate variant for that wave. All samples were from HIV-
443 uninfected individuals who were above 18 years of age and provided consent.
444 Ethical clearance was obtained for each cohort from Human Research Ethics
445 Committees from the University of Pretoria (247/2020) and University of Cape Town
446 (R021/2020).

447

448 *SARS-CoV-2 antigen design and expression*

449 The pseudovirus SARS-CoV-2 Wuhan-1 spike was mutated using the QuikChange
450 Lightning Site-Directed Mutagenesis kit (Agilent Technologies) and NEBuilder HiFi
451 DNA Assembly Master Mix (NEB) into the 614G WT (D614G wild-type), Beta (L18F,
452 D80A, D215G, 242-244del, K417N, E484K, N501Y, D614G and A701V), Delta
453 (T19R, 156-157del, R158G, L452R, T478K, D614G, P681R and D950N), Delta plus
454 (Delta+) (T19R, 156-157del, R158G, K417N, L452R, T478K, D614G, P681R and
455 D950N), Gamma (L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y,
456 D614G, H655Y, T1027I, V1176F) and Omicron (A67V, Δ69-70, T95I, G142D, Δ143-
457 145, Δ211, L212I, 214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S,
458 S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G,
459 H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F). The
460 SARS-CoV-1 spike was obtained from Genscript. Pseudoviruses were prepared as
461 previously described (3). Briefly, human embryonic kidney (HEK) 293T cells were co-

462 transfected with the SARS-CoV-2 spike plasmid of interest together with a firefly
463 luciferase encoding lentivirus backbone plasmid for 72 hours. Culture supernatants
464 were filter-sterilized and stored at -70°C .

465 For soluble proteins, the SARS-CoV-2 D614G spike was obtained from Jason
466 McLellan (University of Texas) and the SARS-CoV-2 RBD WT from Florian
467 Krammer. The full spike proteins were mutated to produce the 614G WT (D614G)
468 and Beta (L18F, D80A, D215G, 242-244del, K417N, E484K, N501Y, D614G and
469 A701V), Delta (T19R, 156-157del, R158G, L452R, T478K, D614G, P681R and
470 D950N, A.VOI.V2 (D80Y, DEL144, I210N, DELN211, D215G, R246M, DEL LAL247-
471 249,W258L, R346K, T478R, E484K, H655Y, P681H, Q957H) and Omicron (BA.1)
472 (A67V, Δ 69-70, T95I, G142D, Δ 143-145, Δ 211, L212I, 214EPE, G339D, S371L,
473 S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S,
474 Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y,
475 N856K, Q954H, N969K, L981F) spike proteins. SARS-CoV-2 subdomain 1 (SBD)
476 protein (residues: 321-591) and N-terminal domain (NTD) protein (residues: 14-304)
477 were designed in-house, ordered from Genscript and cloned into a mammalian cell
478 expression vector. Mutagenesis was used to produce SBD Beta (K417N, E484K or
479 N501Y) SBD K417N, SBD E484K, SBD N501Y single mutants and NTD Beta (L18F,
480 D80A, D215G, 242-244 del). Proteins were expressed in human embryonic kidney
481 HEK293F cells for 6 days, at 37°C , 70% humidity and 10% CO_2 . Purification was
482 carried out using a nickel-charged resin followed by size-exclusion chromatography.
483 Pure protein fractions were collected and frozen at -80°C until further use.

484

485 *SARS-CoV-2 monoclonal antibody isolation*

486 Cryopreserved PBMCs from a SARS-CoV-2-infected participant, SA-01-0084, were
487 stained for SARS-CoV-2-specific B-cell markers before single cell sorting. B-cells
488 marked as CD3-, CD14-, CD16-, CD19+ and Aqua Vital Dye-negative were selected.
489 Biotinylated SARS-CoV-2 Beta and D614G spike antigens were labelled with PE and
490 AF647, respectively, through the biotin-streptavidin interaction. Viable cells that
491 bound the Beta and/or D614G spikes were single-cell sorted into 96 well plates and
492 heavy and light chain genes were PCR amplified.

493

494 *Single cell PCR amplification of heavy and light chain variable genes*

495 Genes encoding IGHV and IGLV chains were amplified from sorted cells by reverse
496 real-time and nested PCR. Reverse transcription was performed using Superscript III
497 reverse transcriptase (Invitrogen) and random hexamer primers (36, 37). Following
498 cDNA synthesis VH, V κ , and V λ antibody genes were amplified as previously
499 described (38, 39). Determination of gene usage was done using IMGT/V-QUEST
500 (https://www.imgt.org/IMGT_vquest/analysis).

501

502 *Pseudovirus-based neutralization assay*

503 Heat-inactivated plasma samples from COVID-19 convalescent donors or mAbs
504 were incubated with the SARS-CoV-2 pseudoviruses for 1 hour at 37°C, 5% CO₂.
505 Subsequently, 1x10⁴ HEK 293T cells engineered to over-express ACE-2, provided
506 by Michael Farzan, were added and incubated at 37°C, 5% CO₂ for 72 hours upon
507 which the luminescence of the luciferase gene was measured. Monoclonal
508 antibodies CB6, CA1 and CR3022 were used as controls.

509

510 *SARS-CoV-2 enzyme linked immunosorbent assay (ELISA)*

511 96-well high-binding plates with 2 μ g/ml of the respective antigen were incubated
512 overnight at 4°C. After blocking with 5% milk powder in 1x PBS and 0.05% Tween-
513 20, mAbs at 5 μ g/ml starting concentration was serially diluted and incubated at
514 room temperature for 1.5 hours. Subsequent washing was followed by the addition of
515 an anti-human horseradish peroxidase secondary antibody diluted to 1:3000 and the
516 plates were incubated for a further 1 hour. TMB substrate (ThermoFisher Scientific)
517 was added, followed by 1M H₂SO₄ to stop the reaction, with absorbance of the
518 reaction measured at an optical density of 450nm. mAbs CR3022, P2B-2FB and
519 Palivizumab served as controls.

520

521 *Antibody-dependent cellular cytotoxicity (ADCC) assay*

522 The ability of the mAb to cross-link between FcγRIIIa (CD16) and spike expressed
523 on cells was used as a proxy for ADCC. To express cell-surface spike, HEK 293T
524 cells were transfected with SARS-CoV-2 614G WT, Beta or Omicron expressing
525 plasmids, with incubation at 37°C over 2 days. Spike expressing cells were
526 incubated with 100 µg/ml of 084-7D or control mAbs titrated four times 1 in 5 in
527 RPMI media, 10% FBS, 1% penicillin-streptomycin for an hour at 37°C. Following
528 this, Jurkat-Lucia™ NFAT-CD16 cells (Invitrogen) were added to the reaction, and
529 incubated for a further 24 hours at 37°C with 10% CO₂. Signal was read on a
530 luminometer by adding 20µl of supernatant and 50µl QUANTI-Luc secreted
531 luciferase to white 96-well plates. CR3022, P2B-2F6 and Palivizumab served as
532 controls and data across spikes were normalized using CR3022.

533

534 *Antibody-dependent cellular phagocytosis (ADCP) assay*

535 Biotinylated SARS-CoV-2 614G WT, Beta and Omicron spike proteins were coated
536 onto beads by incubating fluorescent neutravidin beads with 10 µg/ml antibody for 2
537 hours as described elsewhere (22). Overnight incubation was carried out with
538 monocytic THP-1 cells, followed by analysis on the FACSaria II (BD Biosciences).
539 The percentage of engulfed fluorescent beads within the THP-1 cells multiplied by
540 the geometric mean was calculated and a final phagocytosis score was determined
541 by subtracting the fluorescence score of the no antibody control. CR3022, P2B-2F6
542 and Palivizumab served as controls.

543

544

545

546 **Conflicts of Interest**

547

548 All authors declare no conflicts of interest.

549

550 **Acknowledgements**

551

552 We acknowledge the participants who volunteered for this study. The parental
553 soluble SARS-CoV-2 spike was provided by J McLellan (University of Texas),
554 parental pseudovirus plasmids by Drs E Landais and D Sok (IAVI) and HEK 293T-
555 ACE-2 cells were provided by Dr Michael Farzan (Scripps Research).

556

557 **Funders**

558

559 PLM is supported by the South African Research Chairs Initiative of the Department
560 of Science and Innovation and National Research Foundation of South Africa. This
561 research was supported by the SA Medical Research Council SHIP program and the
562 Bill and Melinda Gates Foundation, through the Global Immunology and Immune
563 Sequencing for Epidemic Response (GIISER) program.

564

565 **Figure legends**

566

567 **Figure 1: Comparison of plasma cross-reactivity elicited by three distinct**
568 **SARS-CoV-2 variants. (A)** Plasma from D614G, Beta and Delta infections during
569 three distinct SARS-CoV-2 waves were tested for neutralization breadth against a
570 range of VOCs using a pseudovirus-based neutralization assay. Fold changes in
571 neutralization are shown above each variant. Plasma neutralization titer is measured
572 as an ID₅₀. Black horizontal bars represent geometric means. The threshold of
573 detection for the neutralization assay is ID₅₀>20. **(B)** Spider plots were derived from
574 GMTs for plasma triggered by D614G, Beta or Delta against multiple VOCs. The
575 GMTs for each plasma set was normalized against titers to the autologous virus and
576 breadth was expressed as area under the curve. **(C)** Plasma from Beta-infected
577 individuals was tested against the Delta and Delta+ variants. Fold changes in
578 neutralization are shown above each variant. Plasma neutralization titer is measured
579 as an ID₅₀. Black horizontal bars represent geometric means. The threshold of
580 detection for the neutralization assay is ID₅₀>20.

581

582 **Figure 2: Characterization of plasma and an isolated monoclonal antibody**
583 **from a Beta-infected individual. (A)** A sequence-confirmed Beta-infected
584 hospitalized individual, SA-01-0084 (084) was selected for this study. Plasma and
585 peripheral blood mononuclear cells were collected 2 days post-positive PCR for
586 further analysis. **(B)** Plasma from SA-01-0084 was tested for neutralization activity in
587 a pseudovirus-based neutralization assay against a range of VOC/VOIs. Plasma
588 neutralization titer is measured as an ID₅₀. The threshold of detection for the
589 neutralization assay is ID₅₀>20. **(C)** The gating strategy for the isolation of SARS-
590 CoV-2 spike-specific B cells via single cell sorting is shown. Each dot represents a
591 cell and the dots in the sorted cell red gate represent Beta spike-positive B cells that
592 had CD3-, CD14-, CD16-, CD19+ markers. These cells were single cell sorted into
593 96 well plates and amplified through antibody gene specific PCR. **(D)** mAb 084-7D
594 was tested for neutralization activity in a pseudovirus-based neutralization assay
595 against the same VOC/VOIs tested with the plasma. mAb neutralization was
596 measured as an IC₅₀ (ug/ml). The threshold of detection for the neutralization assay
597 is IC₅₀>20 ug/ml **(E)** A SARS-CoV-2 ELISA was used to map the specificity of the
598 084-7D mAb. The mAb was tested against the D614G and Beta N-terminal domain,

599 spike and RBD antigens, as well as SBD (subdomain 1) proteins mutated to include
600 Beta-specific SBD single mutants, K417N, E484K and N501Y. The starting
601 concentration of the mAb was 5ug/ml. The threshold of detection for the binding
602 assay is OD450nm>0.04.

603

604 **Figure 3: mAb 084-7D displayed antibody dependent cellular phagocytosis**
605 **(ADCP) and antibody dependent cellular cytotoxicity (ADCC) with cross**
606 **reactivity towards Beta and Omicron. (A)** ADCP activity of mAb 084-7D was
607 measured using THP-1 phagocytosis assay and the phagocytosis score shown as
608 an area under the curve (AUC) measure. The threshold of detection for this assay is
609 AUC>0. **(B)** ADCC activity of mAb 094-7D was measured using an infectious ADCC
610 assay. The % killing activity is shown as an AUC measure. The threshold of
611 detection for the ADCC assay is AUC>8000. In both ADCP and ADCC assays P2B-
612 2F6 was used a positive control for D614G activity, CR3022 was used as a positive
613 control for all variants and Palivizumab, an RSV-specific mAb, was used as a
614 negative control. Experiments were conducted in duplicate and error bars represent
615 the mean with standard deviation of two experiments.

616

617 **Figure 4: Genetic analysis of mAb 084-7D compared to a similar N417-**
618 **dependent mAb. (A)** Heavy chain and **(B)** light chain analysis of mAb 087-7D was
619 conducted using IMGT/V-QUEST (https://www.imgt.org/IMGT_vquest/analysis). A
620 multiple sequence alignment of the germline gene and mAb sequences for 084-7D
621 and CAB-A17 was generated using ClustalW ([https://www.genome.jp/tools-](https://www.genome.jp/tools-bin/clustalw)
622 [bin/clustalw](https://www.genome.jp/tools-bin/clustalw)). Key positions implicated in the development of breadth in the CAB-A17
623 mAb are shown in bold and mutations from germline gene residues in these regions
624 are shown in red.

625

626

627 References

628

- 629 1. Hirabara SM, Serdan TD, Gorjao R, Masi LN, Pithon-Curi TC, Covas DT, Curi
630 R, Durigon EL. 2022. SARS-COV-2 Variants: Differences and Potential of
631 Immune Evasion. *Frontiers in Cellular and Infection Microbiology*:1401.
- 632 2. Tegally H, Wilkinson E, Giovanetti M, Iranzadeh A, Fonseca V, Giandhari J,
633 Doolabh D, Pillay S, San EJ, Msomi N. 2021. Detection of a SARS-CoV-2
634 variant of concern in South Africa. *Nature* 592:438-443.
- 635 3. Wibmer CK, Ayres F, Hermanus T, Madzivhandila M, Kgagudi P, Oosthuysen
636 B, Lambson BE, De Oliveira T, Vermeulen M, Van der Berg K. 2021. SARS-
637 CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor
638 plasma. *Nature medicine* 27:622-625.
- 639 4. Scheepers C, Everatt J, Amoako DG, Tegally H, Wibmer CK, Mnguni A,
640 Ismail A, Mahlangu B, Lambson BE, Richardson SI, Martin DP, Wilkinson E,
641 San JE, Giandhari J, Manamela N, Ntuli N, Kgagudi P, Cele S, Pillay S,
642 Mohale T, Ramphal U, Naidoo Y, Khumalo ZT, Kwatra G, Gray G, Bekker L-
643 G, Madhi SA, Baillie V, Van Voorhis WC, NGS-SA, Treurnicht FK, Venter M,
644 Mlisana K, Wolter N, Sigal A, Williamson C, Hsiao N-y, Msomi N, Mponga T,
645 Preiser W, Makatini Z, Lessells R, Moore PL, de Oliveira T, von Gottberg A,
646 Bhiman JN. 2021. Emergence and phenotypic characterization of C.1.2, a
647 globally detected lineage that rapidly accumulated mutations of concern.
648 medRxiv doi:10.1101/2021.08.20.21262342:2021.08.20.21262342.
- 649 5. Viana R, Moyo S, Amoako DG, Tegally H, Scheepers C, Althaus CL, Anyaneji
650 UJ, Bester PA, Boni MF, Chand M, Choga WT, Colquhoun R, Davids M,
651 Deforche K, Doolabh D, Engelbrecht S, Everatt J, Giandhari J, Giovanetti M,
652 Hardie D, Hill V, Hsiao N-Y, Iranzadeh A, Ismail A, Joseph C, Joseph R,
653 Koopile L, Pond SLK, Kraemer MU, Kuate-Lere L, Laguda-Akingba O,
654 Lesetedi-Mafoko O, Lessells RJ, Lockman S, Lucaci AG, Maharaj A,
655 Mahlangu B, Mponga T, Mahlakwane K, Makatini Z, Marais G, Maruapula D,
656 Masupu K, Matshaba M, Mayaphi S, Mbhele N, Mbulawa MB, Mendes A,
657 Mlisana K, Mnguni A, et al. 2021. Rapid epidemic expansion of the SARS-
658 CoV-2 Omicron variant in southern Africa. medRxiv
659 doi:10.1101/2021.12.19.21268028:2021.12.19.21268028.
- 660 6. de Oliveira T, Lutucuta S, Nkengasong J, Morais J, Paixão JP, Neto Z, Afonso
661 P, Miranda J, David K, Inglês L, Raisa Rivas Carralero APAP, Freitas HR,
662 Mufinda F, Tessema SK, Tegally H, San EJ, Wilkinson E, Giandhari J, Pillay
663 S, Giovanetti M, Naidoo Y, Katzourakis A, Ghafari M, Singh L, Tshiabuila D,
664 Martin D, Lessells RJ. 2021. A novel variant of interest of SARS-CoV-2 with
665 multiple spike mutations detected through travel surveillance in Africa.
666 medRxiv doi:10.1101/2021.03.30.21254323:2021.03.30.21254323.
- 667 7. Sheward DJ, Kim C, Ehling RA, Pankow A, Dopico XC, Martin D, Reddy S,
668 Dillner J, Karlsson Hedestam GB, Albert J, Murrell B. 2021. Variable loss of
669 antibody potency against SARS-CoV-2 B.1.1.529 (Omicron). bioRxiv
670 doi:10.1101/2021.12.19.473354:2021.12.19.473354.
- 671 8. Cele S, Jackson L, Khan K, Khoury D, Moyo-Gwete T, Tegally H, Scheepers
672 C, Amoako D, Karim F, Bernstein M, Lustig G, Archary D, Smith M, Ganga Y,
673 Jule Z, Reedoy K, San JE, Hwa S-H, Giandhari J, Blackburn JM, Gosnell BI,
674 Karim SA, Hanekom W, NGS-SA, Team C-K, von Gottberg A, Bhiman J,
675 Lessells RJ, Moosa M-YS, Davenport M, de Oliveira T, Moore PL, Sigal A.

- 676 2021. Omicron extensively but incompletely escapes Pfizer BNT162b2
677 neutralization. *Nature* doi:10.1038/d41586-021-03824-5.
- 678 9. Garcia-Beltran WF, Denis KJS, Hoelzemer A, Lam EC, Nitido AD, Sheehan
679 ML, Berrios C, Ofoman O, Chang CC, Hauser BM. 2022. mRNA-based
680 COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-
681 2 Omicron variant. *Cell*.
- 682 10. Laurini E, Marson D, Aulic S, Fermeglia A, Pricl S. 2021. Molecular rationale
683 for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and
684 etesevimab monoclonal antibodies. *Scientific Reports* 11:20274.
- 685 11. Arora P, Kempf A, Nehlmeier I, Graichen L, Sidarovich A, Winkler MS, Schulz
686 S, Jäck H-M, Stankov MV, Behrens G. 2021. Delta variant (B. 1.617. 2)
687 sublineages do not show increased neutralization resistance. *Cellular &
688 molecular immunology* 18:2557-2559.
- 689 12. Kumar S, Karuppanan K, Subramaniam G. 2022. Omicron (BA.1) and Sub-
690 Variants (BA.1, BA.2 and BA.3) of SARS-CoV-2 Spike Infectivity and
691 Pathogenicity: A Comparative Sequence and Structural-based Computational
692 Assessment. *bioRxiv* doi:10.1101/2022.02.11.480029:2022.02.11.480029.
- 693 13. Barnes CO, Jette CA, Abernathy ME, Dam K-MA, Esswein SR, Gristick HB,
694 Malyutin AG, Sharaf NG, Huey-Tubman KE, Lee YE. 2020. SARS-CoV-2
695 neutralizing antibody structures inform therapeutic strategies. *Nature*:1-6.
- 696 14. Greaney AJ, Starr TN, Eguia RT, Loes AN, Khan K, Karim F, Cele S, Bowen
697 JE, Logue JK, Corti D. 2022. A SARS-CoV-2 variant elicits an antibody
698 response with a shifted immunodominance hierarchy. *PLoS pathogens*
699 18:e1010248.
- 700 15. Greaney AJ, Eguia RT, Starr TN, Khan K, Franko N, Logue JK, Lord SM,
701 Speake C, Chu HY, Sigal A, Bloom JD. 2022. The SARS-CoV-2 Delta variant
702 induces an antibody response largely focused on class 1 and 2 antibody
703 epitopes. *bioRxiv* doi:10.1101/2022.03.12.484088:2022.03.12.484088.
- 704 16. Piccoli L, Park Y-J, Tortorici MA, Czudnochowski N, Walls AC, Beltramello M,
705 Silacci-Fregni C, Pinto D, Rosen LE, Bowen JE, Acton OJ, Jaconi S, Guarino
706 B, Minola A, Zatta F, Sprugasci N, Bassi J, Peter A, De Marco A, Nix JC, Mele
707 F, Jovic S, Rodriguez BF, Gupta SV, Jin F, Piumatti G, Lo Presti G, Pellanda
708 AF, Biggiogero M, Tarkowski M, Pizzuto MS, Cameroni E, Havenar-Daughton
709 C, Smithey M, Hong D, Lepori V, Albanese E, Ceschi A, Bernasconi E, Elzi L,
710 Ferrari P, Garzoni C, Riva A, Snell G, Sallusto F, Fink K, Virgin HW,
711 Lanzavecchia A, Corti D, Veesler D. 2020. Mapping Neutralizing and
712 Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain
713 by Structure-Guided High-Resolution Serology. *Cell* 183:1024-1042.e21.
- 714 17. Greaney AJ, Loes AN, Gentles LE, Crawford KH, Starr TN, Malone KD, Chu
715 HY, Bloom JD. 2021. Antibodies elicited by mRNA-1273 vaccination bind
716 more broadly to the receptor binding domain than do those from SARS-CoV-2
717 infection. *Science translational medicine* 13:eabi9915.
- 718 18. Moyo-Gwete T, Madzivhandila M, Makhado Z, Ayres F, Mhlanga D,
719 Oosthuysen B, Lambson BE, Kgagudi P, Tegally H, Iranzadeh A, Doolabh D,
720 Tyers L, Chinhoyi LR, Mennen M, Skelem S, Marais G, Wibmer CK, Bhiman
721 JN, Ueckermann V, Rossouw T, Boswell M, de Oliveira T, Williamson C,
722 Burgers WA, Ntusi N, Morris L, Moore PL. 2021. Cross-Reactive Neutralizing
723 Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351). *New
724 England Journal of Medicine* doi:10.1056/NEJMc2104192:2161-2163.

- 725 19. Cele S, Karim F, Lustig G, San JE, Hermanus T, Tegally H, Snyman J, Moyo-
726 Gwete T, Wilkinson E, Bernstein M. 2022. SARS-CoV-2 prolonged infection
727 during advanced HIV disease evolves extensive immune escape. *Cell host &*
728 *microbe* 30:154-162. e5.
- 729 20. Liu C, Ginn HM, Dejnirattisai W, Supasa P, Wang B, Tuekprakhon A, Nutalai
730 R, Zhou D, Mentzer AJ, Zhao Y. 2021. Reduced neutralization of SARS-CoV-
731 2 B. 1.617 by vaccine and convalescent serum. *Cell* 184:1-17.
- 732 21. Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, Maguire TJA,
733 Hallett SR, Pickering S, Charalampous T, Alcolea-Medina A, Huettnner I,
734 Jimenez-Guardeño JM, Acors S, Almeida N, Cox D, Dickenson RE, Galao
735 RP, Kouphou N, Lista MJ, Ortega-Prieto AM, Wilson H, Winstone H, Fairhead
736 C, Su JZ, Nebbia G, Batra R, Neil S, Shankar-Hari M, Edgeworth JD, Malim
737 MH, Doores KJ. 2021. Neutralizing antibody activity in convalescent sera from
738 infection in humans with SARS-CoV-2 and variants of concern. *Nature*
739 *Microbiology* 6:1433-1442.
- 740 22. Richardson SI, Madzorera VS, Spencer H, Manamela NP, van der Mescht
741 MA, Lambson BE, Oosthuysen B, Ayres F, Makhado Z, Moyo-Gwete T. 2022.
742 SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector
743 functions in previously vaccinated, but not unvaccinated individuals. *Cell Host*
744 *& Microbe*.
- 745 23. Teyssou E, Delagrèverie H, Visseaux B, Lambert-Niclot S, Briclher S, Ferre V,
746 Marot S, Jary A, Todesco E, Schnuriger A. 2021. The Delta SARS-CoV-2
747 variant has a higher viral load than the Beta and the historical variants in
748 nasopharyngeal samples from newly diagnosed COVID-19 patients. *Journal*
749 *of Infection* 83:e1-e3.
- 750 24. Wilks SH, Mühlemann B, Shen X, Türelı S, LeGresley EB, Netzl A, Caniza
751 MA, Chacaltana-Huarcaya JN, Daniell X, Datto MB, Denny TN, Drosten C,
752 Fouchier RAM, Garcia PJ, Halfmann PJ, Jassem A, Jones TC, Kawaoka Y,
753 Krammer F, McDanal C, Pajon R, Simon V, Stockwell M, Tang H, van Bakel
754 H, Webby R, Montefiori DC, Smith DJ. 2022. Mapping SARS-CoV-2 antigenic
755 relationships and serological responses. *bioRxiv*
756 doi:10.1101/2022.01.28.477987:2022.01.28.477987.
- 757 25. Reincke SM, Yuan M, Kornau H-C, Corman VM, van Hoof S, Sánchez-Sendin
758 E, Ramberger M, Yu W, Hua Y, Tien H. 2022. SARS-CoV-2 Beta variant
759 infection elicits potent lineage-specific and cross-reactive antibodies. *Science*
760 375:782-787.
- 761 26. Richardson SI, Manamela NP, Motsoeneng BM, Kaldine H, Ayres F, Makhado
762 Z, Mennen M, Skelem S, Williams N, Sullivan NJ. 2022. SARS-CoV-2 Beta
763 and Delta variants trigger Fc effector function with increased cross-reactivity.
764 *Cell Reports Medicine*:100510.
- 765 27. Zohar T, Loos C, Fischinger S, Atyeo C, Wang C, Slein MD, Burke J, Yu J,
766 Feldman J, Hauser BM. 2020. Compromised humoral functional evolution
767 tracks with SARS-CoV-2 mortality. *Cell* 183:1508-1519. e12.
- 768 28. Sheward DJ, Pushparaj P, Das H, Kim C, Kim S, Hanke L, Dyrdak R,
769 McInerney GM, Albert J, Murrell B. 2022. Structural basis of Omicron
770 neutralization by affinity-matured public antibodies. *bioRxiv*.
- 771 29. Yuan M, Liu H, Wu NC, Lee C-CD, Zhu X, Zhao F, Huang D, Yu W, Hua Y,
772 Tien H, Rogers TF, Landais E, Sok D, Jardine JG, Burton DR, Wilson IA.
773 2020. Structural basis of a shared antibody response to SARS-CoV-2.
774 *Science* 369:1119-1123.

- 775 30. Ju B, Zhang Q, Ge J, Wang R, Sun J, Ge X, Yu J, Shan S, Zhou B, Song S,
776 Tang X, Yu J, Lan J, Yuan J, Wang H, Zhao J, Zhang S, Wang Y, Shi X, Liu
777 L, Zhao J, Wang X, Zhang Z, Zhang L. 2020. Human neutralizing antibodies
778 elicited by SARS-CoV-2 infection. *Nature* 584:115-119.
- 779 31. Xu H, Wang B, Zhao T-N, Liang Z-T, Peng T-B, Song X-H, Wu J-J, Wang Y-
780 C, Su X-D. 2021. Structure-based analyses of neutralization antibodies
781 interacting with naturally occurring SARS-CoV-2 RBD variants. *Cell Research*
782 31:1126-1129.
- 783 32. Cao Y, Su B, Guo X, Sun W, Deng Y, Bao L, Zhu Q, Zhang X, Zheng Y, Geng
784 C. 2020. Potent neutralizing antibodies against SARS-CoV-2 identified by
785 high-throughput single-cell sequencing of convalescent patients' B cells. *Cell*
786 182:73-84. e16.
- 787 33. Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D,
788 Wang Z, Lorenzi JC, Flyak AI, DeLaitch AT, Huey-Tubman KE. 2021. Affinity
789 maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth,
790 and resilience to viral escape mutations. *Immunity* 54:1853-1868. e7.
- 791 34. Derdeyn CA, Moore PL, Morris L. 2014. Development of broadly neutralizing
792 antibodies from autologous neutralizing antibody responses in HIV infection.
793 *Curr Opin HIV AIDS* 9:210-6.
- 794 35. Klein F, Diskin R, Scheid Johannes F, Gaebler C, Mouquet H, Georgiev IS,
795 Pancera M, Zhou T, Incesu R-B, Fu Brooks Z, Gnanapragasam Priyanthi NP,
796 Oliveira Thiago Y, Seaman Michael S, Kwong Peter D, Bjorkman Pamela J,
797 Nussenzweig Michel C. 2013. Somatic Mutations of the Immunoglobulin
798 Framework Are Generally Required for Broad and Potent HIV-1
799 Neutralization. *Cell* 153:126-138.
- 800 36. Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H.
801 2008. Efficient generation of monoclonal antibodies from single human B cells
802 by single cell RT-PCR and expression vector cloning. *J Immunol Methods*
803 329:112-24.
- 804 37. Scheid JF, Mouquet H, Ueberheide B, Diskin R, Klein F, Oliveira TY, Pietzsch
805 J, Fenyo D, Abadir A, Velinzon K. 2011. Sequence and structural
806 convergence of broad and potent HIV antibodies that mimic CD4 binding.
807 *Science* 333:1633-1637.
- 808 38. Doria-Rose NA, Bhiman JN, Roark RS, Schramm CA, Gorman J, Chuang GY,
809 Pancera M, Cale EM, Ernandes MJ, Louder MK, Asokan M, Bailer RT, Druz
810 A, Fraschilla IR, Garrett NJ, Jarosinski M, Lynch RM, McKee K, O'Dell S,
811 Pegu A, Schmidt SD, Staube RP, Sutton MS, Wang K, Wibmer CK, Haynes
812 BF, Abdool-Karim S, Shapiro L, Kwong PD, Moore PL, Morris L, Mascola JR.
813 2015. New Member of the V1V2-Directed CAP256-VRC26 Lineage That
814 Shows Increased Breadth and Exceptional Potency. *J Virol* 90:76-91.
- 815 39. Liao H-X, Levesque MC, Nagel A, Dixon A, Zhang R, Walter E, Parks R,
816 Whitesides J, Marshall DJ, Hwang K-K. 2009. High-throughput isolation of
817 immunoglobulin genes from single human B cells and expression as
818 monoclonal antibodies. *Journal of virological methods* 158:171-179.
- 819






Figure 1

A

Sample ID	SA-01-0084
Sex	Female
Age	55-60
HIV status	Uninfected
Days post-positive RT-PCR test	2 days
Date blood sample collected	January 2021
Beta infection sequence confirmed	Yes







Figure 2




Figure 3

A

mAb 084-7D heavy chain

mAb ID	Isolated as	Cloned as	Gene usage			V-gene Mutation frequency	CDRH3 length	CDRH3 AA Sequence
			VH	D	J			
084-7D	IgG1, IgA1, IgM	IgG1	3-23*01	2-8*01	1*01	5,9%	13	AKDHPSWGSSFLN

```

      1              20              40
VH3-23*01  EVQLLESGGG LVQPGGSLRL SCAAS GFTFS SYAMSWVRQA PGKGLEWVSA
VH3-53*01  EVQLVESGGG LIQPGGSLRL SCAAS GFTVS SNYMSWVRQA PGKGLEWVSV
CAB-A17-HC DVHLVESGG- LIQPGGSLRL SCAAS EFIVS ANYMSWVRQA PGEGLQWVSV
084-7D HC   EVQLLESGGG LVQPGGSLRL SCAAS GFSFS SYAMNWVRQA PGKGLEWVSA

      60              80
VH3-23*01  ISGSGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAK
VH3-53*01  IY-SGGSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCAR
CAB-A17-HC IY-PGGSTFY AESVKGRFTI SRDNSRNTLY LQMNSLRAED TGVYYCAR
084-7D HC   ISGGGDNIYY ADSVKGRFTI SRDNYKNTLH LQMKSLRAED TAVYYCAK
  
```

B

mAb 084-7D light chain

mAb ID	Gene usage		V-gene Mutation frequency	CDRL3 length	CDRL3 AA Sequence
	VK	J			
084-7D	1-5*03	4*01	2,9%	9	QQYNSYSLT

```

      1              20              40
VK1-5*03   DIQMTQSPST LSASVGDRVT ITCRASQS I-SSWLAWYQQK PGKAPKLLIY
VK3-20*01 EIVLTQSPGT LSLSPGERAT LSCRASQS VSSSYLAWYQQK PGQAPRLLIY
CAB-A17-LC EIVLTQSPGT LSLSPGERAS LSCRASQS LS-TYLAWYQQK PGQAPRLLIF
084-7D LC  DIQMTQSPST LSASVGDRVT ITCRASQS I-SSWLAWYQQK PGRAPKLLIY

      60              80
VK1-5*03   KASSLESQVP SRFSGSGSGT EFTLTISLQ PDDFATYYCQ QYNSYS
VK3-20*01 GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSP
CAB-A17-LC GASSRASGIP DRFSGGGSGT DFTLTISRLE PEDFAVYYCQ QYGSSP
084-7D LC  TASNLESQVP SRFSGSGSGT EFSLTISLQ PDDFATYYCQ QYNSYS
  
```

Figure 4